Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives

References

• Ameri P, Ferone D. Diffuse endocrine system, neuroendocrine tumors and immunity: what’s new? Neuroendocrinology. 2012;95(4):267–276.
   PubMed Web of Science ®Google Scholar
• Rosai J. The origin of neuroendocrine tumors and the neural crest saga. Mod Pathol. 2011;24(Suppl 2):S53–7.
   PubMedGoogle Scholar
• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342.
   PubMed Web of Science ®Google Scholar
• O’Shea T, Druce M. When should genetic testing be performed in patients with neuroendocrine tumours? Rev Endocr Metab Disord. 2017;18(4):499–515.
   PubMed Web of Science ®Google Scholar
• Ida A, Okubo Y, Kasajima R, et al. Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: histological features for accurate diagnosis and toward future novel therapies. Pathol Res Pract. 2022;229:153731.
   PubMed Web of Science ®Google Scholar
• Massironi S, Campana D, Pusceddu S, et al. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: data from a retrospective multi-centric study. Dig Liver Dis. 2021;53(3):367–374.
   PubMedGoogle Scholar
• Feola T, Puliani G, Sesti F, et al. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study. J Endocrinol Invest. 2022;45(4):849–857.
   PubMed Web of Science ®Google Scholar
• Barrea L, Muscogiuri G, Modica R, et al. Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors. Front Endocrinol (Lausanne). 2021;12:649496.
   PubMed Web of Science ®Google Scholar
• Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17(16):2191–2205.
   PubMed Web of Science ®Google Scholar
• Riihimäki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139(12):2679–2686.
   PubMed Web of Science ®Google Scholar
• Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep. 2021;23(4):43.
   PubMed Web of Science ®Google Scholar
• Zatelli MC, Guadagno E, Messina E, et al. Open issues on G3 neuroendocrine neoplasms: back to the future. Endocr Relat Cancer. 2018;25(6):R375–R384.
   PubMed Web of Science ®Google Scholar
• Board. WCoTE. Digestive system tumours. Lyon (France):International Agency for Research on cancer;2019. WHO classification of tumours seires tev.
   Google Scholar
• Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10(9):1240–1242.
   PubMed Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072.
   PubMed Web of Science ®Google Scholar
• Pavel M, Valle JW, Eriksson B, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy - biotherapy and novel targeted agents. Neuroendocrinology. 2017;105(3):266–280.
   PubMed Web of Science ®Google Scholar
• Del Prete M, Fiore F, Modica R, et al. Hepatic arterial embolization in patients with neuroendocrine tumors. J Exp Clin Cancer Res. 2014;33(1):43.
   PubMedGoogle Scholar
• Faggiano A, Di Maio S, Mocerino C, et al. Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine. 2019;66(2):417–424.
   PubMed Web of Science ®Google Scholar
• [cited 2022 Feb 1]. https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf .
   Google Scholar
• Scandurra C, Modica R, Maldonato NM, et al. Quality of life in patients with neuroendocrine neoplasms: the role of severity, clinical heterogeneity, and resilience. J Clin Endocrinol Metab. 2021;106(1):e316–e327.
   PubMed Web of Science ®Google Scholar
• Faggiano A, Lo Calzo F, and Pizza G, et al. The safety of available treatments options for neuroendocrine tumors. Expert Opin Drug Saf. 2017;16(10): 1149–1161. .
   PubMed Web of Science ®Google Scholar
• Modlin IM, Pavel M, Kidd M, et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–188.
   PubMed Web of Science ®Google Scholar
• Oberg K. Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology. 2004;80(Suppl 1):57–61.
   PubMedGoogle Scholar
• Grozinsky-Glasberg S, Shimon I, Korbonits M, et al. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer. 2008;15(3):701–720.
   PubMed Web of Science ®Google Scholar
• Narayanan S, Kunz PL. Role of somatostatin analogues in the treatment of neuroendocrine tumors. J Natl Compr Canc Netw. 2015;13(1):109–117. quiz 117.
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707–716.
   PubMed Web of Science ®Google Scholar
• Toumpanakis C, Garland J, Marelli L, et al. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment Pharmacol Ther. 2009;30(7):733–740.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Wolin EM, Liyanage N, et al. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (elect): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22(9):1068–1080.
   PubMed Web of Science ®Google Scholar
• Fisher GA, Wolin EM, Liyanage N, et al. Patient-reported symptom control of diarrhea and flushing in patients with neuroendocrine tumors treated with lanreotide depot/autogel: results from a randomized, placebo-controlled, double-blind and 32-Week Open-Label Study. Oncologist. 2018;23(1):16–24.
   PubMed Web of Science ®Google Scholar
• Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17(12):1733–1742.
   PubMed Web of Science ®Google Scholar
• Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008;13(13):822–840.
   PubMedGoogle Scholar
• Chan DL, Ferone D, Albertelli M, et al. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. Endocrine. 2017;57(3):366–375.
   PubMed Web of Science ®Google Scholar
• Rinke A, Müller -H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–4663.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–233.
   PubMed Web of Science ®Google Scholar
• Rinke A, Wittenberg M, Schade-Brittinger C, et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology. 2017;104(1):26–32.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Ćwikła JB, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191–199.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Phan AT, et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021;71(2):502–513.
   PubMed Web of Science ®Google Scholar
• Brighi N, Panzuto F, Modica R, et al. Biliary stone disease in patients with neuroendocrine tumors treated with somatostatin analogs: a Multicenter Study. Oncologist. 2020;25(3):259–265.
   PubMed Web of Science ®Google Scholar
• Ferolla P, Faggiano A, Grimaldi F, et al. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Invest. 2012;35(3):326–331.
   PubMed Web of Science ®Google Scholar
• Lamberti G, Faggiano A, Brighi N, et al. Nonconventional doses of somatostatin analogs in patients with progressing well-differentiated neuroendocrine tumor. J Clin Endocrinol Metab. 2020;105(1):194–200.
   Web of Science ®Google Scholar
• Hofland LJ, Lamberts SWJ. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24(1):28–47.
   PubMed Web of Science ®Google Scholar
• Pavel M, Ćwikła JB, Lombard-Bohas C, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur J Cancer. 2021;157:403–414.
   PubMed Web of Science ®Google Scholar
• Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (Nen) and nen of unknown primary site. Neuroendocrinology. 2016;103(2):172–185.
   PubMed Web of Science ®Google Scholar
• Baudin E, Caplin M, and Garcia-Carbonero R, et al., Lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021;32(4): 439–451. .
   PubMed Web of Science ®Google Scholar
• Laskaratos F-M, Walker M, Naik K, et al. Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours. Br J Cancer. 2016;115(11):1321–1327.
   PubMed Web of Science ®Google Scholar
• Faggiano A, Carratù AC, Guadagno E, et al. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. Oncotarget. 2016;7(5):5538–5547.
   PubMedGoogle Scholar
• Haug AR, Rominger A, Mustafa M, et al. Treatment with octreotide does not reduce tumor uptake of 68 Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med. 2011;52(11):1679–1683.
   PubMed Web of Science ®Google Scholar
• Yordanova A, Wicharz MM, Mayer K, et al. The role of adding somatostatin analogues to peptide receptor radionuclide therapy as a combination and maintenance therapy. Clin Cancer Res. 2018;24(19):4672–4679.
   PubMed Web of Science ®Google Scholar
• Syguła A, Ledwon A, Hasse-Lazar K, et al. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2022. DOI:10.1007/s00259-022-05792-y.
   PubMed Web of Science ®Google Scholar
• [cited 2022 Feb 1] https://doi.org/10.1016/j.annonc.2020.08.1374
   Google Scholar
• Faggiano A, Modica R, and Lo Calzo F, et al. Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors < 2 centimeters. J Clin Endocrinol Metab. 2020;105(1):dgz007. DOI: 10.1210/clinem/dgz007.
   Web of Science ®Google Scholar
• Sandostatin LAR and Axitinib vs Pbo in Pnts with advanced well-differentiated non-pancreatic neuroendocrine carcinomas. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT01744249
   Google Scholar
• Non-functioning pancreatic neuroendocrine tumors in MEN1: somatostatin Analogs Versus NO Treatment. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT02705651
   Google Scholar
• A Phase II Study of ramucirumab with somatostatin analog therapy in patients with advanced PCTPIS of RWSAT in PWAPCT. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT02795858
   Google Scholar
• Study of lanreotide in patients with metastatic gastrointestinal neuroendocrine tumors who are undergoing liver-directed radioembolization with Yttrium-90 microspheres. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT02859064
   Google Scholar
• A trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in GEP. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT04427787
   Google Scholar
• Study to assess the efficacy and safety of lanreotide Autogel® in Chinese participants with GEP-NETs. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT04852679
   Google Scholar
• Cabozantinib and lanreotide as treatment for gastroenteropancreatic neuroendocrine tumors. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT05048901
   Google Scholar
• A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT05050942
   Google Scholar
• van Fraeyenhove F, Meireson N, Terriere L, et al. High-dose lanreotide in the treatment of poorly differentiated pancreatic neuroendocrine carcinoma: a case report. Case Rep Oncol. 2014;7(1):155–163.
   PubMedGoogle Scholar
• Pavel M, Öberg K, and Falconi M, et al., Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7): 844–860. .
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–523.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513.
   PubMed Web of Science ®Google Scholar
• Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–977.
   PubMed Web of Science ®Google Scholar
• Wolin EM. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett. 2013;335(1):1–8.
   PubMed Web of Science ®Google Scholar
• Grozinsky-Glasberg S, Franchi G, Teng M, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology. 2008;87(3):168–181.
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26(26):4311–4318.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–2012.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Baudin E, Öberg KE, et al. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol. 2017;28(7):1569–1575.
   PubMed Web of Science ®Google Scholar
• Faggiano A, Malandrino P, Modica R, et al. Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: a comprehensive review of literature. Oncologist. 2016;21(7):875–886.
   PubMed Web of Science ®Google Scholar
• Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother. 2018;19(8):909–928.
   PubMed Web of Science ®Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69–76.
   PubMed Web of Science ®Google Scholar
• Bajetta E, Catena L, Fazio N, et al. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Cancer. 2014;120(16):2457–2463.
   PubMed Web of Science ®Google Scholar
• Chan JA, Ryan DP, Zhu AX, et al. Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer. 2012;19(5):615–623.
   PubMed Web of Science ®Google Scholar
• Ferolla P, Brizzi MP, Meyer T, et al. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2017;18(12):1652–1664.
   PubMed Web of Science ®Google Scholar
• Baudin E, Berruti A, Mario G, et al. First long-term results on efficacy and safety of long-acting pasireotide in combination with everolimus in patients with advanced carcinoids (NET) of the lung/thymus: phase II LUNA trial. J Clin Oncol. 2021 May 28;39(15_suppl):8574.
   Web of Science ®Google Scholar
• Panzuto F, Rinzivillo M, Fazio N, et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. 2014;19(9):966–974.
   PubMed Web of Science ®Google Scholar
• Gallo M, Malandrino P, Fanciulli G, et al. Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. J Cancer Res Clin Oncol. 2017;143(7):1209–1224.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009;360(2):195–197.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Akcakanat A, Chen H, et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012;18(6):1777.
   PubMed Web of Science ®Google Scholar
• Martins D, Spada F, Lambrescu I, et al. Predictive markers of response to everolimus and sunitinib in neuroendocrine tumors. Target Oncol. 2017;12(5):611–622.
   PubMed Web of Science ®Google Scholar
• Scoazec J-Y. Angiogenesis in neuroendocrine tumors: therapeutic applications. Neuroendocrinology. 2013;97(1):45–56.
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25–35.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Lenz H-J, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26(20):3403–3410.
   PubMed Web of Science ®Google Scholar
• Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol. 2017;28(2):339–343.
   PubMed Web of Science ®Google Scholar
• Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects systematic review and meta-regression analysis. JAMA. 2010;303(12):1180–1187.
   PubMed Web of Science ®Google Scholar
• Mathew A, Führer D, Lahner H. Sunitinib-induced hypothyroidism and survival in pancreatic neuroendocrine tumors. Hormone Metab Res. 2021;53(12):794–800.
   PubMed Web of Science ®Google Scholar
• Rinzivillo M, Fazio N, Pusceddu S, et al. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: a real-world study. Pancreatology. 2018;18(2):198–203.
   PubMed Web of Science ®Google Scholar
• Gao H, Dong J, Zhang W, et al. Sequential capecitabine/temozolomide and sunitinib treatment in patients with metastatic well-differentiated grade 1/grade 2 pancreatic neuroendocrine tumors. Endocr Pract. 2022;28(3):292–297.
   PubMedGoogle Scholar
• Zurita AJ, Khajavi M, H-K W, et al. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. Br J Cancer. 2015;112(7):1199–1205.
   PubMed Web of Science ®Google Scholar
• Testing Lutetium Lu 177 dotatate in patients with somatostatin receptor positive advanced bronchial neuroendocrine tumors. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT04665739
   Google Scholar
• Lenvatinib and everolimus in treating patients with advanced UCT. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT03950609
   Google Scholar
• A Study of LEE011 with everolimus in patients with advanced neuroendocrine tumors. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT03070301
   Google Scholar
• Efficacy and safety of 177Lu-edotreotide PRRT in GEP-NET patients. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT03049189
   Google Scholar
• Cisplatinum and everolimus in patients with metastatic or unresectable NEC of extrapulmonary origin. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT02695459
   Google Scholar
• Efficacy and safety of everolimus and (STZ-5FU) given one upfront the other upon progression in advanced pancreatic neuroendocrine tumor (pNET). [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT02246127
   Google Scholar
• antitumor efficacy of peptide receptor radionuclide therapy with 177lutetium -octreotate randomized vs sunitinib in unresectable progressive well-differentiated neuroendocrine pancreatic tumor: first randomized phase II. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT02230176
   Google Scholar
• Everolimus and octreotide acetate with or without bevacizumab in treating patients with locally advanced or metastatic pancreatic neuroendocrine tumors that cannot be removed by surgery. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT01229943
   Google Scholar
• Pellat A, Dreyer C, Couffignal C, et al. Clinical and biomarker evaluations of sunitinib in patients with grade 3 digestive neuroendocrine neoplasms. Neuroendocrinology. [cited 2022 Feb 1]. 2018;107(1):24–31.
   PubMed Web of Science ®Google Scholar
• Uccelli L, Boschi A, Cittanti C, et al. 90Y/177Lu-DOTATOC: from preclinical studies to application in humans. Pharmaceutics. [cited 2022 Feb 1]. 2021;13(9):1463.
   PubMed Web of Science ®Google Scholar
• Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105(3):295–309.
   PubMed Web of Science ®Google Scholar
• Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177 Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–135.
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Caplin ME, Kunz PL, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752–1763.
   PubMed Web of Science ®Google Scholar
• Sansovini M, Severi S, Ambrosetti A, et al. Treatment with the radiolabelled somatostatin analog 177Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology. 2013;97(4):347–354.
   PubMed Web of Science ®Google Scholar
• Haug AR. PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme? EJNMMI Res. 2020;10(1):35.
   PubMed Web of Science ®Google Scholar
• Delpassand ES, Samarghandi A, Zamanian S, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014;43(4):518–525.
   PubMed Web of Science ®Google Scholar
• Strosberg J, Wolin E, Chasen B, et al. Health-related QUALITY of life in patients with progressive midgut neuroendocrine tumors treated with 177 Lu-Dotatate in the Phase III NETTER-1 trial. J Clin Oncol. 2018;36(25):2578–2584.
   PubMed Web of Science ®Google Scholar
• Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177 Lu-Octreotate. J Nucl Med. 2014;55(2):183–190.
   PubMed Web of Science ®Google Scholar
• Sabet A, Dautzenberg K, Haslerud T, et al. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging. 2015;42(8):1238–1246.
   PubMed Web of Science ®Google Scholar
• Pauwels E, van Binnebeek S, Vandecaveye V, et al. Inflammation-based index and 68 Ga-DOTATOC PET–derived uptake and volumetric parameters predict outcome in neuroendocrine tumor patients treated with 90 Y-DOTATOC. J Nucl Med. 2020;61(7):1014–1020.
   PubMed Web of Science ®Google Scholar
• Bodei L, Kidd M, Modlin IM, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2016;43(5):839–851.
   PubMed Web of Science ®Google Scholar
• Albertelli M, Dotto A, Di Dato C, et al. PRRT: identikit of the perfect patient. Rev Endocr Metab Disord. 2021;22(3):563–579.
   PubMed Web of Science ®Google Scholar
• Mariniello A, Bodei L, Tinelli C, et al. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging. 2016;43(3):441–452.
   PubMed Web of Science ®Google Scholar
• Lania A, Ferraù F, Rubino M, et al. Neoadjuvant Therapy for neuroendocrine neoplasms: recent progresses and future approaches. Front Endocrinol (Lausanne). 2021;12:651438.
   PubMed Web of Science ®Google Scholar
• Carlsen EA, Fazio N, Granberg D, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic Nen G3: a multicenter cohort study. Endocr Relat Cancer. 2019;26(2):227–239.
   PubMed Web of Science ®Google Scholar
• Ostwal V, Basu S, Bhargava P, et al. Capecitabine-temozolomide in advanced grade 2 and grade 3 neuroendocrine neoplasms: benefits of chemotherapy in neuroendocrine neoplasms with significant 18FDG uptake. Neuroendocrinology. 2021;111(10):998–1004.
   PubMed Web of Science ®Google Scholar
• Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors,version 2.2021,NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(7):839–868.
   PubMedGoogle Scholar
• Spada F, Antonuzzo L, Marconcini R, et al. Oxaliplatin-based chemotherapy in advanced neuroendocrine tumors: clinical outcomes and preliminary correlation with biological factors. Neuroendocrinology. 2016;103(6):806–814.
   PubMed Web of Science ®Google Scholar
• Capecitabine T and B for M or UPNT. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT01525082
   Google Scholar
• Temozolomide with or without capecitabine in treating patients with advanced pancreatic neuroendocrine tumors. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT01824875.
   Google Scholar
• Cisplatin C and E or T and C in TPWNC of the GT or PTIM or CBR by S. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT02595424
   Google Scholar
• Assessment of the efficacy of bevacizumab in combination with folfiri as second-line treatment in patients suffering from an advanced inoperable poorly differentiated neuroendocrine carcinoma of an unknown or gastroentero-pancreatic primary cancer. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT02820857
   Google Scholar
• Second-line therapy for patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. Cited: 1 February 2022. https://ClinicalTrials.gov/show/NCT03837977
   Google Scholar
• Platinum-doublet chemotherapy and nivolumab for the treatment of subjects with neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or of unknown (UK) origin. [cited 2022 Feb 1]. https://ClinicalTrials.gov/show/NCT03980925
   Google Scholar
• Meyer T, Qian W, Caplin ME, et al. Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. Eur J Cancer. 2014;50(5):902–911.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Hornick JL, Frauenhoffer C, et al. O 6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15(1):338–345.
   PubMed Web of Science ®Google Scholar
• Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13(10):2986–2991.
   PubMed Web of Science ®Google Scholar
• Crona J, Fanola I, Lindholm DP, et al. Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology. 2013;98(2):151–155.
   PubMed Web of Science ®Google Scholar
• Tafuto S, von Arx C, and Capozzi M, et al. Safety and activity of metronomic temozolomide in second-line treatment of advanced neuroendocrine neoplasms. J Clin Med. 2019;8(8):1224. DOI: 10.3390/jcm8081224.
   Web of Science ®Google Scholar
• Ramirez RA, Beyer DT, Chauhan A, et al. The Role of Capecitabine/Temozolomide in metastatic neuroendocrine tumors. Oncologist. 2016;21(6):671–675.
   PubMed Web of Science ®Google Scholar
• Claringbold PG, Turner JH. Pancreatic neuroendocrine tumor control: durable objective response to combination 177Lu-Octreotate-Capecitabine-Temozolomide radiopeptide chemotherapy. Neuroendocrinology. 2016;103(5):432–439.
   PubMed Web of Science ®Google Scholar
• Cives M, Ghayouri M, Morse B, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016;23(9):759–767.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–160.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Rinke A, Valle JW, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms. Systemic therapy 2: chemotherapy. Neuroendocrinology. 2017;105:281–294.
   PubMed Web of Science ®Google Scholar
• Frizziero M, Spada F, Lamarca A, et al. Carboplatin in combination with oral or intravenous etoposide for extra-pulmonary, poorly-differentiated neuroendocrine carcinomas. Neuro-endocrinology. 2019;109(2):100–112.
   PubMed Web of Science ®Google Scholar
• Fanciulli G, Di Molfetta S, and Dotto A, et al. Emerging therapies in pheochromocytoma and paraganglioma: immune checkpoint inhibitors in the starting blocks. J Clin Med. 2020;10(1):88. DOI: 10.3390/jcm10010088.
   PubMed Web of Science ®Google Scholar
• Colao A, de Nigris F, Modica R, et al. Clinical epigenetics of neuroendocrine tumors: the road ahead. Front Endocrinol (Lausanne). 2020;11:604341.
   PubMed Web of Science ®Google Scholar